Recognizes a protein of 42-46kDa, identified as MAGE-1. This mAb does not cross-react with other members of MAGE-family. Human malignant neoplasms carry rejection antigens that are recognized by the patients' autologous, tumor directed and specific, cytolytic, CD8+ T lymphocyte clones (CTL). The MAGE family of genes codes an important group of antigens. It was identified that melanomas and primary glial brain tumors express common melanoma associated antigens (MAAs). Because MAGE-1 is expressed on a significant proportion of human neoplasms of various histological types (melanoma, brain tumors of glial origin, neuroblastoma, non-small cell lung cancer, breast, gastric, colorectal, ovarian, renal cell carcinomas) and not on normal tissues, the encoded antigen may serve as a marker of early detection and target for cancer immunotherapy.

Flow Cytometry: 0.5-1 ug/million cells in 0.1ml Immunofluorescence: 0.5-1 ug/ml Immunohistology (FFPE): 0.5-1 ug/ml for 30 min at RT (1) Prediluted format : incubate for 30 min at RT (2) Optimal dilution of the MAGE-1 antibody should be determined by the researcher.

1. Staining of formalin-fixed tissues requires boiling tissue sections in 10mM citrate buffer, pH 6.0, for 10-20 min followed by cooling at RT for 20 min.
2. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.

Type: Primary
Antigen: MAGEA1
Clonality: Monoclonal
Clone: MZ2E/838
Conjugation: Unconjugated
Epitope:
Host: Mouse
Isotype: IgG1, kappa
Reactivity: Human